eligibility_summary
Eligibility: ≥18, consentable, diffuse pleural mesothelioma, ≥1 prior systemic therapy, measurable disease, biopsies pre‑C1D1 and pre‑C3D1 if safe, ECOG 0 or KPS ≥70, adequate organ function, contraception if applicable. Exclude: recent investigational/anti‑cancer therapy, sacituzumab govitecan/irinotecan allergy, unresolved toxicity, interfering psych/substance issues, active second cancer (some exceptions), uncontrolled HBV/HCV/HIV, recent MI/ACS/stroke/TIA/CABG, CHF (NYHA III–IV/recent admit), pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Sacituzumab govitecan-hziy (SG), an antibody–drug conjugate (ADC). Composition/mechanism: a humanized anti–Trop-2 IgG1 monoclonal antibody linked via a cleavable linker to SN-38, the active metabolite of irinotecan (a camptothecin topoisomerase I inhibitor). After binding Trop-2 on tumor cells, SG is internalized and releases SN-38, inhibiting topoisomerase I, inducing DNA damage and apoptosis, cleavable linker allows bystander killing. Potential Fc-mediated effector functions may contribute. Targets: Trop-2–expressing mesothelioma cells, DNA replication/topoisomerase I pathway in tumor cells. Trial: Phase 2, single-arm, previously treated diffuse pleural mesothelioma.